A detailed history of Covestor LTD transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Covestor LTD holds 4 shares of PTGX stock, worth $138. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4
Previous 5 20.0%
Holding current value
$138
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$21.79 - $32.15 $21 - $32
-1 Reduced 20.0%
4 $0
Q3 2023

Nov 13, 2023

SELL
$16.68 - $23.66 $16 - $23
-1 Reduced 16.67%
5 $0
Q2 2023

Aug 11, 2023

SELL
$18.02 - $29.36 $72 - $117
-4 Reduced 40.0%
6 $0
Q4 2022

Feb 13, 2023

BUY
$7.36 - $11.17 $73 - $111
10 New
10 $0
Q2 2022

Aug 10, 2022

SELL
$7.06 - $25.52 $14 - $51
-2 Reduced 18.18%
9 $0
Q1 2022

May 13, 2022

SELL
$23.34 - $36.08 $70 - $108
-3 Reduced 21.43%
11 $0
Q4 2021

Feb 10, 2022

BUY
$17.63 - $37.1 $246 - $519
14 New
14 $0

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.7B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Covestor LTD Portfolio

Follow Covestor LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.